Private Wealth Partners LLC bought a new stake in InVitae Corp (NASDAQ:NVTA) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 98,000 shares of the medical research company’s stock, valued at approximately $918,000. Private Wealth Partners LLC owned approximately 0.20% of InVitae Corp at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. lifted its stake in InVitae Corp by 27.0% in the first quarter. Schwab Charles Investment Management Inc. now owns 104,994 shares of the medical research company’s stock valued at $1,162,000 after acquiring an additional 22,301 shares during the last quarter. Vanguard Group Inc. lifted its stake in InVitae Corp by 9.8% in the first quarter. Vanguard Group Inc. now owns 1,206,266 shares of the medical research company’s stock valued at $13,341,000 after acquiring an additional 107,775 shares during the last quarter. Gamco Investors INC. ET AL lifted its stake in InVitae Corp by 326.6% in the second quarter. Gamco Investors INC. ET AL now owns 122,000 shares of the medical research company’s stock valued at $1,166,000 after acquiring an additional 93,405 shares during the last quarter. Donald L. Hagan LLC lifted its stake in InVitae Corp by 30.0% in the second quarter. Donald L. Hagan LLC now owns 13,000 shares of the medical research company’s stock valued at $124,000 after acquiring an additional 3,000 shares during the last quarter. Finally, Swiss National Bank acquired a new stake in InVitae Corp in the second quarter valued at $438,000.

InVitae Corp (NASDAQ NVTA) traded down $0.38 during midday trading on Monday, hitting $8.62. 346,700 shares of the stock were exchanged, compared to its average volume of 319,546. InVitae Corp has a one year low of $5.76 and a one year high of $11.88.

COPYRIGHT VIOLATION WARNING: “Private Wealth Partners LLC Acquires New Stake in InVitae Corp (NVTA)” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.watchlistnews.com/private-wealth-partners-llc-acquires-new-stake-in-invitae-corp-nvta/1700435.html.

A number of brokerages have commented on NVTA. Zacks Investment Research cut shares of InVitae Corp from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. BidaskClub upgraded shares of InVitae Corp from a “sell” rating to a “hold” rating in a research note on Thursday, August 3rd. J P Morgan Chase & Co reiterated an “overweight” rating and issued a $15.00 price target (up previously from $14.00) on shares of InVitae Corp in a research note on Wednesday, August 9th. Finally, Leerink Swann cut their price target on shares of InVitae Corp from $14.00 to $12.00 and set an “outperform” rating for the company in a research note on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $13.50.

InVitae Corp Company Profile

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Want to see what other hedge funds are holding NVTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InVitae Corp (NASDAQ:NVTA).

Institutional Ownership by Quarter for InVitae Corp (NASDAQ:NVTA)

Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.